UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors

Brief description of study

The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Incurable Platinum Refractory Germ Cell Tumors, Tumors
  • Age: - 99 Years
  • Gender: All
Updated on 29 Jan 2020. Study ID: 832068

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center